Bavarian Nordic (OTCMKTS:BVNRY) Sees Large Volume Increase – What’s Next?

Bavarian Nordic (OTCMKTS:BVNRY) saw unusually-strong trading volume on Tuesday . Approximately 3,047 shares traded hands during mid-day trading, an increase of 92% from the previous session’s volume of 1,589 shares.The stock last traded at $10.17 and had previously closed at $10.1460.

Bavarian Nordic Stock Up 0.2%

The firm has a market cap of $2.42 billion, a P/E ratio of 6.56 and a beta of 1.36. The company has a fifty day simple moving average of $10.09 and a 200-day simple moving average of $11.04.

Bavarian Nordic (OTCMKTS:BVNRY) last released its quarterly earnings data on Friday, November 14th. The company reported $0.72 earnings per share for the quarter. The firm had revenue of $281.11 million during the quarter. Bavarian Nordic had a return on equity of 20.47% and a net margin of 35.96%. As a group, research analysts forecast that Bavarian Nordic will post 0.67 EPS for the current year.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.